Source: Butterfly Network Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Datametrex (DM) subsidiary Medi-Call has added a cutting-edge Health Canada approved portable ultrasound device, Butterfly iQ+
  • The device provides imaging and diagnostic tools to Medi-Call physicians during home and in-clinic visits
  • The company welcomes Dr. Rashad Dindo to the Medi-Call team
  • Medi-Call is a subscription-based software as a service (SaaS) mobile application that connects patients with doctors
  • Datametrex AI Limited (DM) opened trading at C$0.10

Datametrex (DM) subsidiary Medi-Call has introduced a cutting-edge Health Canada-approved portable ultrasound device, Butterfly iQ+.

This device is used to aid in assessments during home and in-clinic visits by Medi-Call physicians.

Butterfly iQ+ features

  • Basic Imaging
  • Whole-body assessments
  • Data storage
  • Diagnostic tools
  • Procedural tools

The company has added Dr. Rashad Dindo to the Medi-Call team.

Marshall Gunter, CEO of Datametrex, commented on the news.

“We are thrilled to expand Medi-Call by offering new ultrasound services. Recent data shows wait times for services like ultrasounds can be up to 3-4 weeks. Being able to provide timely care for patients in a way that is accessible is priority.” 

Omar Sharif, Chief Medical Officer of Medi-Call, added,

“The team is excited to have the latest in portable ultrasound technology at our fingertips. These devices allow our physicians to serve patient needs better, and faster by having accessible and on the go equipment, catering to numerous health services, and ultimately more efficient care.” 

Medi-Call is a subscription-based software as a service (SaaS) mobile application that connects patients with doctors.

Datametrex AI Limited (DM) opened trading at C$0.10.


More From The Market Herald
Clear Blue Technologies - CEO, Miriam Tuerk.

" Clear Blue Technologies (TSXV:CBLU) receives $5M grant funding from SDTC

Clear Blue Technologies International (CBLU) is part of a cohort of six innovative Canadian companies selected to receive a cumulative $18.7 million in...

" BetterLife (CSE:BETR) files a comprehensive patent for BETR-001 and other LSD derivatives

BetterLife Pharma (BETR) filed a PCT patent application and a U.S. application for lysergic acid diethylamide (LSD) derivatives, including 2-bromo-LSD.